Beractant

Form: Intratracheal suspension

Strength: 25 mg/mL

Reference Brands: Survanta(US & EU)

Category: Respiratory Disorder

Beractant, marketed as Survanta, is a bovine-derived pulmonary surfactant used for the prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants. Each mL contains 25 mg of phospholipids, available in 4 mL (100 mg) and 8 mL (200 mg) single-use vials. Beractant is administered via intratracheal instillation to reduce surface tension in the lungs and improve neonatal respiratory function. Approved by the FDA and widely used in the US and EU, Survanta is a critical product in NICUs worldwide. Trusted by neonatologists, it is a top-choice surfactant for neonatal care and B2B sourcing.